Ustekinumab: cutaneous disorders, malignancies, infections.
D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D001424:Bacterial Infections / Q000139:chemically induced* / Q000276:immunology / Q000382:microbiology; D018450:Disease Progression; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D009369:Neoplasms / Q000139:chemically induced* / Q000276:immunology; D061214:Patient Safety; D011565:Psoriasis / Q000175:diagnosis / Q000188:drug therapy*; D018570:Risk Assessment; D012307:Risk Factors; D012720:Severity of Illness Index; D016896:Treatment Outcome; D000069549:Ustekinumab; D014777:Virus Diseases / Q000139:chemically induced* / Q000276:immunology / Q000382:microbiology
D061067:Antibodies, Monoclonal, Humanized; D007166:Immunosuppressive Agents; D000069549:Ustekinumab